期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 37, 期 9, 页码 789-806出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2016.05.010
关键词
-
资金
- Indian Council of Medical Research
- Science Engineering Research Board [SB/EMEQ-389/2015 (P-07/598)]
- Department of Biotechnology, Government of India [BT/PR6712/MED/30/873/2012 (P07/564)]
- University Grant Commission
- Banaras Hindu University (BHU), India
- Science and Engineering Research Board, India [ECR/2016/000034]
The fruit fly Drosophila melanogaster has been used for modeling cancer and as an in vivo tool for the validation and/or development of cancer therapeutics. The impetus for the use of Drosophila in cancer research stems from the high conservation of its signaling pathways, lower genetic redundancy, short life cycle, genetic amenability, and ease of maintenance. Several cell signaling pathways in Drosophila have been used for cancer drug development. The efficacy of combination therapy and uptake/bioavailability of drugs have also been studied. Drosophila has been validated using several FDA-approved drugs, suggesting a potential application of this model in drug repurposing. The model is emerging as a powerful tool for high-throughput screening and should significantly reduce the cost and time associated with drug development. In this review we discuss the applications of Drosophila in cancer drug development. The advantages and limitations of the model are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据